{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSS%2C+Microsatellite+Stable+Colon+Cancer&page=2", "query": { "condition": "MSS, Microsatellite Stable Colon Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSS%2C+Microsatellite+Stable+Colon+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T16:42:45.992Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07281716", "title": "Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "Nadunolimab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Feng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-12-01", "completion_date": "2028-12-15", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281716" }, { "nct_id": "NCT04126733", "title": "Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" }, { "name": "Nivolumab (Opdivo)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2019-10-14", "completion_date": "2022-03-28", "has_results": true, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 15, "location_summary": "Duarte, California • Denver, Colorado • Miami, Florida + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04126733" }, { "nct_id": "NCT03631407", "title": "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Vicriviroc", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-09-24", "completion_date": "2021-06-08", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631407" }, { "nct_id": "NCT05178576", "title": "A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "Gevokizumab", "type": "DRUG" }, { "name": "Signatera test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-06-24", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 5, "location_summary": "Gainesville, Florida • Iowa City, Iowa • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05178576" }, { "nct_id": "NCT02860546", "title": "A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Metastatic Colorectal Cancer" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-08-29", "completion_date": "2017-09-07", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 3, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02860546" }, { "nct_id": "NCT03189030", "title": "Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "pLADD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aduro Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-05-02", "completion_date": "2020-09-02", "has_results": false, "last_update_posted_date": "2020-10-01", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 5, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03189030" }, { "nct_id": "NCT04044430", "title": "Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer", "Stage III Colorectal Cancer", "Stage III Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Colorectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Colorectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Colorectal Cancer", "Stage IIIC Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Colorectal Cancer", "Stage IV Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Colorectal Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Rectal Cancer", "Stage IVC Colon Cancer", "Stage IVC Colorectal Cancer", "Stage IVC Rectal Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-08-31", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044430" }, { "nct_id": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07826390", "type": "DRUG" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "SOC (anti-PD-1 + platinum -based chemo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-09-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 8, "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546553" }, { "nct_id": "NCT07321106", "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Colorectal Cancer (CRC)", "Colorectal (Colon or Rectal) Cancer", "CRC", "Metastatic Colon Cancer", "Colon Cancer", "Advanced Colorectal Cancer" ], "interventions": [ { "name": "CBI-1214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cartography Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-01-15", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 8, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07321106" }, { "nct_id": "NCT03800602", "title": "Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colorectal Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer", "Stage IVC Colorectal Cancer", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2019-01-15", "completion_date": "2021-09-04", "has_results": true, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-06-10T16:42:45.992Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03800602" } ] }